3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Leukemia, Myeloid, Acute
21
Leukemia, Lymphocytic, Chronic, B-Cell
14
Leukemia
14
Precursor Cell Lymphoblastic Leukemia-Lymphoma
12
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
10
Hematologic Neoplasms
10
Recurrence
8
Myelodysplastic Syndromes
8
Lymphoma, Non-Hodgkin
4
Multiple Myeloma
3
Lymphoma, B-Cell, Marginal Zone
3
Lymphoma
3
Hematologic Diseases
3
Philadelphia Chromosome
2
Neoplasms
2
Myeloproliferative Disorders
2
Mastocytosis, Systemic
2
Lymphoproliferative Disorders
2
Lymphoma, Mantle-Cell
2
Lymphoma, Follicular
2
Lymphoma, B-Cell
2
Leukemia, Mast-Cell
2
Leukemia, Hairy Cell
2
Leukemia, Biphenotypic, Acute
2
Glioma
2
Burkitt Lymphoma
2
Bronchiolitis Obliterans Syndrome
2
Bone Marrow Diseases
2
Blastic Plasmacytoid Dendritic Cell Neoplasm
2
Waldenstrom Macroglobulinemia
1
Interventions
nilotinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has announcements
×
Neoplastic Processes
×
Other hematologic neoplasm
×
Clear all
NCT01844765
2021-04-22
DIALOG
Novartis
Phase 2
Completed
59 enrolled
33 charts
1 FDA